Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
COR is heading into its November 4 earnings date with the stock up 2.9% on the week, analysts lifting targets, and short sellers quietly retreating, a setup that looks more constructive than it has for much of 2026.
The lending market tells a story of minimal bear conviction. Short interest has fallen roughly 7% over the past month to 2.1% of the free float, a low and still-declining figure. Availability is essentially unlimited, with borrow supply dwarfing the shares already lent out. Cost to borrow, while nominally up on the week, remains a fraction of a percent at 0.43%, well within easy-borrow territory. Options traders are similarly relaxed: the put/call ratio at 0.35 is slightly below its 20-day average of 0.37, close to the low end of the past year's range of 0.23 to 0.84. There is no sign of defensive hedging or short-side pressure building ahead of the print.
The Street is broadly constructive, and the most recent action reinforces that. Leerink Partners raised its price target to $388 from $380 this week, maintaining an Outperform. JPMorgan and Wells Fargo both lifted targets after the August earnings beat, with Wells moving to $395 and JPMorgan going to $390, both Overweight. Morgan Stanley also nudged its target higher. The outlier is Bank of America, which held Neutral with a $285 target, well below where the stock is trading now at $316, making it a clear contrarian voice on valuation. The mean analyst target across the group is $369, implying roughly 17% upside from the current price. On valuation, the trailing PE has eased about 2.6 points over the past 30 days to 14.6x, which is relatively undemanding for a large-cap healthcare distributor. EV/EBITDA has also compressed slightly over the same period. The EPS momentum factor scores are a genuine standout: 95th percentile on 30-day momentum and 85th on 90-day, reflecting a string of estimate revisions running firmly in one direction.
One name on the 13D register is worth flagging. Walgreens Boots Alliance Holdings LLC filed a Schedule 13D/A in June 2025, carrying a disclosed stake of 4.96%, down from 5.4% previously. A 13D filing signals that the investor has or had activist intent. The stake has declined over multiple amendments, and as of the most recent filing, it sits just below the 5% threshold. Under SEC rules, a holder that drops below 5% is not required to file again, so the current position could be materially different from what is disclosed. BlackRock reported 9.5% of shares, T. Rowe Price 7.6%, and JP Morgan Asset Management added roughly 1.2 million shares in the most recent quarter, a notable addition from a major institutional holder.
Insider activity over the past 90 days has been net negative. The largest single transaction was an EVP sale of roughly 11,300 shares worth $3.7 million in late August, conducted outside a 10b5-1 plan. A director sold $411,000 worth in September, also outside a plan. The chief accounting officer sold smaller amounts across two transactions under a pre-arranged 10b5-1 plan, which carries less signalling weight. Grant activity was routine. The net result is about 14,500 shares sold on a net basis over 90 days, a mild negative flag but not unusual for a stock that has recovered after a difficult stretch.
Wikipedia page views for Cencora are running at a z-score of 2.4 against the company's own 90-day history, a notable uptick in retail attention though this dataset has not been measured as a lead indicator for any financial metric. The next earnings date is 28 days away, and with a stock that jumped over 6% on the day of its last August print, the proximity of that event is the clearest thing to watch between now and then.
See the live data behind this article on ORTEX.
Open COR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
